Related Experiment Videos
Inhibition of DNA synthesis in human gliomas by roscovitine
J S Yakisich1, J Boethius, I O Lindblom
1Applied Biochemistry, Clinical Research Center, Huddinge, Sweden.
Abstract:
The early effect of 1-100 microM roscovitine, a purine analogue and cyclin-dependent kinase inhibitor, was studied on tissue specimens from eight human malignant gliomas. The tissue was incubated immediately after resection with DMEM containing [3H]methylthymidine plus vehicle alone or the proper concentration of roscovitine for 30-90 min. The DNA synthesis rate was assessed by measurement of [3H]methylthymidine incorporation into trichloroacetic acid insoluble material/mg protein/min. In all gliomas, 100 microM roscovitine inhibited DNA synthesis by 71-97% (average 89 +/- 8%, p<0.0001). This inhibitory effect of roscovitine appeared within 30 min of incubation and was concentration dependent.
Insights
Roscovitine, a cyclin-dependent kinase inhibitor, significantly reduced DNA synthesis in human malignant gliomas. This potent effect was observed rapidly and was concentration-dependent, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Malignant gliomas are aggressive brain tumors with limited treatment options.
- Cyclin-dependent kinases (CDKs) play a crucial role in cell cycle progression and are often dysregulated in cancer.
- Roscovitine is a CDK inhibitor with potential anti-cancer properties.
Purpose of the Study:
- To investigate the early effects of roscovitine on DNA synthesis in human malignant glioma tissue.
- To determine the concentration-dependency and time-course of roscovitine's inhibitory action.
Main Methods:
- Human malignant glioma tissue specimens were obtained immediately after resection.
- Tissue was incubated with [3H]methylthymidine and varying concentrations of roscovitine or vehicle control.
- DNA synthesis rate was quantified by measuring [3H]methylthymidine incorporation into DNA.
Main Results:
- Roscovitine significantly inhibited DNA synthesis in all tested glioma specimens.
- Inhibition ranged from 71% to 97%, with an average of 89% at 100 microM concentration.
- The inhibitory effect was observed within 30 minutes and was dose-dependent.
Conclusions:
- Roscovitine demonstrates potent and rapid inhibition of DNA synthesis in human malignant gliomas.
- These findings support roscovitine's potential as a therapeutic agent for malignant gliomas.
- Further research into roscovitine's efficacy and safety in glioma treatment is warranted.